[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373717":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":28,"collaborators":31,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"I.M. Sechenov First Moscow State Medical University","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":7,"zip":13,"country":14,"countryCode":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"Institute for Urology and Reproductive Health, Sechenov University.","RECRUITING","Moscow","119991","Russia","RU",{"type":17,"coordinates":18},"Point",[19,20],37.61781,55.75204,{"lat":20,"lon":19},[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Dmitry Enikeev, MD, PhD","CONTACT","+7 925 517 79 26","enikeev-dv@1msmu.ru",{"type":29,"investigatorFullName":24,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Deputy director for Research, Institute for Urology and Reproductive Health",[32,35],{"name":33,"class":34},"Moscow Regional Research and Clinical Institute (MONIKI)","OTHER_GOV",{"name":36,"class":6},"Pirogov Russian National Research Medical University","100373717",false,"NCT04146077","Active Surveillance for Low Risk Prostate Cancer","Active Surveillance Methodology for Low Risk Prostate Cancer","Inclusion Criteria:\n\n* prostate adenocarcinoma verified by at least 12 core biopsy\n* patient must understand the sense of research, agree to participate and sign a form of agreement\n* low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA\\\u003C10 ng\u002Fml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)\n* not more than 33% cores with adenocarcinoma\n\nExclusion Criteria:\n\n* previous treatment of prostate cancer\n* other prostatic malignant neoplasms\n* other oncological diseases\n* treatment with 5-alfa-reductase inhibitors\n* patient's refuse to continue study\n* patient's desire to begin treatment","MALE","50 Years","75 Years",{"count":47,"type":48},100,"ESTIMATED","OBSERVATIONAL","An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.",[52,53],"Prostate Cancer","Prostate Adenocarcinoma",[55,56,57],"prostate cancer","active surveillance","low oncological risk","2021-07-21",{"date":60,"type":61},"2021-07-22","ACTUAL",{"date":63,"type":61},"2019-10-01",{"date":65,"type":48},"2026-10",{"name":5,"class":6},1]